Display options
Cite
Baker KE, Curtis MJ. Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism. Br J Pharmacol. 2004;142(2):352-66doi: 10.1038/sj.bjp.0705767.
Baker, K. E., & Curtis, M. J. (2004). Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism. British journal of pharmacology, 142(2), 352-66. https://doi.org/10.1038/sj.bjp.0705767
Baker, Kathryn E, and Curtis, Michael J. "Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism." British journal of pharmacology vol. 142,2 (2004): 352-66. doi: https://doi.org/10.1038/sj.bjp.0705767
Baker KE, Curtis MJ. Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism. Br J Pharmacol. 2004 May;142(2):352-66. doi: 10.1038/sj.bjp.0705767. Epub 2004 Apr 05. PMID: 15066909; PMCID: PMC1574949.
Copy Download .nbib Format: NLM
Share it on

Br J Pharmacol. 2004 May;142(2):352-66. doi: 10.1038/sj.bjp.0705767. Epub 2004 Apr 05.

Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism.

British journal of pharmacology

Kathryn E Baker, Michael J Curtis

Affiliations

  1. Cardiovascular Research, Rayne Institute, St. Thomas' Hospital, London SE17EH, UK.

PMID: 15066909 PMCID: PMC1574949 DOI: 10.1038/sj.bjp.0705767

Abstract

Various putative drug targets for suppression of ischaemia-induced ventricular fibrillation (VF) have been proposed, but therapeutic success in the suppression of sudden cardiac death (SCD) has been disappointing. Platelet-activating factor (PAF) is a known component of the ischaemic milieu. We examined its arrhythmogenic activity, and its interaction with two other putative mediators, norepinephrine and K(+), using an ischaemia-free in vitro heart bioassay, and a specific PAF antagonist (BN-50739). PAF (0.1-100 nmol) was administered selectively to the left coronary bed of rat isolated hearts using a specially designed catheter. In some hearts, PAF was administered to the left coronary bed during concomitant regional perfusion with norepinephrine and/or K(+). In separate studies, PAF accumulation in the perfused cardiac tissue was evaluated using (3)H-PAF. PAF evoked ventricular arrhythmias concentration-dependently (P<0.05). It also widened QT interval and reduced coronary flow selectively in the PAF-exposed left coronary bed (both P<0.05). Two exposures of hearts to PAF were necessary to evoke the QT and rhythm effects. The PAF-induced arrhythmias and coronary vasoconstriction were partially suppressed by the PAF antagonist BN-50739 (10 microm), although BN-50739 itself widened QT interval. K(+) (8 and 15 mm) unexpectedly antagonised the arrhythmogenic effects of PAF without itself eliciting arrhythmias (P<0.05). Norepinephrine (0.1 microm) had little or no effect on the actions of PAF, while failing to evoke arrhythmias itself. Nevertheless, the combination of 15 mm K(+) and 0.1 microm norepinephrine evoked arrhythmias of a severity similar to arrhythmias evoked by PAF alone, without adding to or diminishing the arrhythmogenic effects of PAF. (3)H-PAF accumulated in the cardiac tissue, with 43+/-5% still present 5 min after bolus administration, accounting for the need for two exposures of the heart to PAF for evocation of arrhythmias. Thus, PAF, by activating specific receptors in the ventricle, can be expected to contribute to arrhythmogenesis during ischaemia. However, its interaction with other components of the ischaemic milieu is complex, and selective block of its actions (or its accumulation) in the ischaemic milieu is alone unlikely to reduce VF/SCD.

References

  1. Cardiovasc Res. 1991 May;25(5):391-7 - PubMed
  2. J Cardiovasc Pharmacol. 1991 Sep;18(3):445-56 - PubMed
  3. Am J Physiol. 1991 Dec;261(6 Pt 2):H2082-90 - PubMed
  4. Cardiovasc Res. 1991 Dec;25(12):1010-22 - PubMed
  5. Circ Res. 2000 Oct 27;87(9):825-30 - PubMed
  6. Br J Pharmacol. 2002 Feb;135(3):807-15 - PubMed
  7. Circ Res. 2002 Oct 18;91(8):662-71 - PubMed
  8. Pharmacol Ther. 2003 Oct;100(1):89-99 - PubMed
  9. J Cardiovasc Pharmacol. 2003 Nov;42(5):612-21 - PubMed
  10. Circ Res. 1973 Nov;33(5):521-31 - PubMed
  11. Pflugers Arch. 1976 Sep 30;365(2-3):99-106 - PubMed
  12. Prostaglandins. 1976 Dec;12(6):897-913 - PubMed
  13. J Clin Invest. 1980 Jan;65(1):161-71 - PubMed
  14. Circ Res. 1980 May;46(5):634-46 - PubMed
  15. Circ Res. 1980 Aug;47(2):151-65 - PubMed
  16. J Mol Cell Cardiol. 1980 Jun;12(6):579-93 - PubMed
  17. J Pharmacol Exp Ther. 1981 Apr;217(1):157-61 - PubMed
  18. Thromb Res. 1983 Apr 1;30(1):71-9 - PubMed
  19. Br J Pharmacol. 1983 May;79(1):265-71 - PubMed
  20. Cardiovasc Res. 1984 Nov;18(11):675-82 - PubMed
  21. Am Heart J. 1985 Feb;109(2):421-30 - PubMed
  22. Lab Invest. 1985 Jun;52(6):617-30 - PubMed
  23. Br J Pharmacol. 1986 Jan;87(1):265-77 - PubMed
  24. Br J Pharmacol. 1986 Jul;88(3):595-605 - PubMed
  25. Circ Res. 1987 Aug;61(2):157-65 - PubMed
  26. J Immunol. 1987 Oct 1;139(7):2439-46 - PubMed
  27. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7557-61 - PubMed
  28. Cardiovasc Res. 1987 Oct;21(10):737-46 - PubMed
  29. Mol Pharmacol. 1989 Jan;35(1):48-58 - PubMed
  30. J Am Coll Cardiol. 1989 Mar 15;13(4):941-50 - PubMed
  31. J Mol Cell Cardiol. 1989 Jan;21(1):21-40 - PubMed
  32. Cardiovasc Res. 1988 Jul;22(7):447-55 - PubMed
  33. FASEB J. 1989 Jul;3(9):2007-18 - PubMed
  34. N Engl J Med. 1989 Aug 10;321(6):406-12 - PubMed
  35. J Mol Cell Cardiol. 1989 Jun;21(6):625-37 - PubMed
  36. Mol Cell Biochem. 1990 Mar 5;93(1):69-76 - PubMed
  37. N Engl J Med. 1990 Jul 5;323(1):27-36 - PubMed
  38. J Cardiovasc Pharmacol. 1990 Nov;16(5):727-32 - PubMed
  39. Br J Pharmacol. 1990 Nov;101(3):734-8 - PubMed
  40. Br J Pharmacol. 1991 Dec;104(4):773-5 - PubMed
  41. Cardiovasc Res. 1992 Apr;26(4):309-15 - PubMed
  42. J Immunol. 1992 Dec 1;149(11):3682-8 - PubMed
  43. Biochem Biophys Res Commun. 1992 Dec 15;189(2):617-24 - PubMed
  44. Br J Pharmacol. 1993 Jan;108(1):139-45 - PubMed
  45. Cardiovasc Res. 1993 Mar;27(3):453-8 - PubMed
  46. Circulation. 1993 Jun;87(6):1979-89 - PubMed
  47. Cardiovasc Res. 1993 May;27(5):703-19 - PubMed
  48. J Cardiovasc Pharmacol. 1993 Sep;22(3):343-9 - PubMed
  49. J Pharmacol Exp Ther. 1994 May;269(2):589-95 - PubMed
  50. J Pharmacol Exp Ther. 1994 Aug;270(2):520-7 - PubMed
  51. Biochem J. 1997 Mar 1;322 ( Pt 2):603-8 - PubMed
  52. J Cardiovasc Pharmacol. 1998 Oct;32(4):621-8 - PubMed
  53. Br J Pharmacol. 1999 Jan;126(1):264-8 - PubMed
  54. J Cardiovasc Pharmacol. 1999 Sep;34(3):394-401 - PubMed
  55. Circ Res. 1985 Nov;57(5):668-75 - PubMed
  56. J Cardiovasc Pharmacol. 1995 Aug;26(2):280-8 - PubMed
  57. J Cardiovasc Electrophysiol. 1995 Nov;6(11):1039-62 - PubMed
  58. Lancet. 1996 Jul 6;348(9019):7-12 - PubMed
  59. Naunyn Schmiedebergs Arch Pharmacol. 1995 Nov;352(5):491-6 - PubMed
  60. Eur J Cell Biol. 1996 Jan;69(1):86-98 - PubMed
  61. J Mol Cell Cardiol. 1995 Dec;27(12):2595-606 - PubMed
  62. J Cardiovasc Electrophysiol. 1996 Feb;7(2):120-33 - PubMed

Substances

MeSH terms

Publication Types